Figure 1 | Scientific Reports

Figure 1

From: A New Approach to Deliver Anti-cancer Nanodrugs with Reduced Off-target Toxicities and Improved Efficiency by Temporarily Blunting the Reticuloendothelial System with Intralipid

Figure 1

Treatment protocols for animal experiments. (A) Treatment protocol for using multiple-doses of Intralipid 20% to investigate the delivery of two doses of DACHPt/HANP. Rats (N = 6 for each group, i.e., Intralipid-treated group and control group) were treated with DACHPt/HANP (2 mg Pt/kg) intravenously twice a week (on Days 1 and 5). Also on Days 1 and 5, Intralipid was intravenously administered at a dosage of 2 g/kg 1 hr before the administration of the nanodrug. On Days 2, 3, 6, and 7, the rats were administered 2 g/kg of Intralipid 20% each day. (B) Treatment protocol for using Intralipid to investigate the delivery of three FDA-approved nanodrugs, Abraxane, Marqibo, and Onivyde. Intralipid was administered intravenously at 2 g/kg 1 hr before the treatment with the nanodrug. After 1 hr, Abraxane, Marqibo, or Onivyde was administered intravenously to a rat at the clinical dose (44 mg/kg, 0.38 mg/kg, and 11.86 mg/kg, respectively). The second dose of Intralipid (2 g/kg) was administered 24-hr post nanodrug treatment. For Abraxane experiment, N = 4 for each group, i.e., the Intralipid-treated group and the control group; for Marqibo and Onivyde experiment, N = 6 for each group. In all the animal experiments, PBS was administered to the control animals.

Back to article page